Immune checkpoint inhibitors (ICIs) such as programmed cell death receptor 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and Cytotoxic T lymphocyte associate protein-4 (CTLA-4) monoclonal antibodies have been shown an effective way to reduce tumor size, slow tumor progression, and prolonging overall survival of patients [3, 4]. The gene discussed is CTLA4; the disease is neoplasm.